Iressa治疗复发或转移性头颈鳞状细胞癌的临床研究  

Clinical study of Iressa for the treatment of recurrent and metastatic head and neck squamous cell carcinoma

作　　者：武要洪[1] 孙传政[1] 李晓江[1] 邓莅霏[2] 李科[1] 费继敏[1] 王虎[1] 

机构地区：[1]云南省肿瘤医院,云南昆明650118 [2]江西省肿瘤医院头颈科,江西南昌330029

出　　处：《现代肿瘤医学》2011年第6期1109-1112,共4页Journal of Modern Oncology

基　　金：云南省应用基础研究计划面上项目(编号:2007C149M);云南省教育厅科学研究基金项目(编号:07Y40515)

摘　　要：目的:探讨Iressa治疗复发或转移性头颈鳞状细胞癌的疗效和安全性。方法:对接受过二线化疗方案(至少一个化疗方案包括铂类)失败的复发或转移性头颈鳞状细胞癌患者,给予Iressa每日250mg口服,持续到患者出现不可接受的不良反应或疾病进展。结果:15例患者入组,Iressa 250mg日/口服治疗能够很好耐受,只出现1级和2级不良反应,但全组无1例患者获得部分反应或全消,中位疾病进展时间为4个月,中位总生存时间为16个月。结论:Iressa能够很好耐受,但是该组患者有效率很低,它在头颈鳞状细胞癌的使用除临床研究外不推荐使用。Objective：To study the safety and initial efficacy of Iressa in patients with recurrent and metastatic head and neck squamous cell carcinomas（HNSCC） pretreated with platinum-based chemotherapy.Methods： Patients with recurrent and metastatic HNSCC who had treatment failure with at least 2 lines of chemotherapy including platinum were given Iressa at a fixed dose of 250mg daily.Treatment was continued until the patient experienced unacceptable side effects or disease progression.Results： Fifteen patients were enrolled.Treatment was well tolerated,and only grades 1 to 2 adverse events were observed.None of the patients achieved partial or complete response.Median time-to-progression was 4 months,and median overall survival was 16 months.Conclusion： Iressa was well tolerated,but the response rate was poor in this heavily pretreated study population,and its use in HNSCC is not recommended outside the context of clinical trial.

关 键 词：头颈鳞状细胞癌 IRESSA 表皮生长因子受体 复发 远处转移 

分 类 号：R739.91[医药卫生—肿瘤]